This short article describes how Organovo is using a novel technology called bioprinting to produce liver and kidney tissues that could help reshape the way drugs are tested and organs are transplanted in our days. It also discusses the challenges and potential effects on society.
BenevolentAI is using machine learning to gather insights from the body of pharmaceutical literature in order to produce new potential drugs, but can it keep top talent?
The discovery of groundbreaking medical treatments may no longer solely rest in the hands of scientists; grassroots R&D efforts combine scientific expertise with the experiences and creativity and horsepower of the masses.
BenevolentAI is a UK-based biotechnology company betting on machine learning and artificial intelligence as their competitive advantage at all stages of the drug development process. Will this bet pay off or will BenevolentAI fail to create meaningful innovation in the biotech space?
Have the economics of investing in new drug discovery and development become so unattractive that investment in new drugs will come to a halt? GlaxoSmithKline and other bio-pharmaceutical companies are turning to machine learning as a potential solution to make the drug discovery process more efficient, with the hopes of greatly reducing both the time and cost associated with R&D.
This article explains how GSK is using machine learning to increase R&D productivity and accelerating drug development timelines.
Machine learning has been touted as a potential cure-all for high drug prices. A number of leading biopharmaceutical companies like Roche have made some large bets in using artificial intelligence tools to improve drug development, but it remains to be seen if machine learning is living up to its hype.
A look at GlaxoSmithKline's efforts to incorporate machine learning into their drug development processes.
Clinical trial delays can result in lost revenue to drug firms of $600k – $8 million per day, not to mention additional lost lives as life-saving treatments wait in the wings . Patient recruitment is the number one cause of clinical trial delays and cost overruns, and Acurian has led the digital transformation of the recruitment process. The Company better identifies and targets appropriate populations through its 17 million patient database and population mapping algorithms .
GSK needs to carefully evaluate incorporating 3D printing in its supply chain before disrupters steal its market share.